Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate - Pfizer

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Pfizer

Alternative Names: GSK 134612; MenACWY - GlaxoSmithKline; MenACWY conjugated vaccine - GlaxoSmithKline; MenACWY-TT; Nimenrix

Latest Information Update: 31 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 31 Mar 2021 Pfizer initiates a phase IIIb trial for Meningococcal infections (Prevention, In infants) in Finland (IM, Injection) (EudraCT2020-005059-19)
  • 18 Apr 2020 Favourable pooled immunogenicity and adverse events data from multiple trials in Meningococcal infections presented at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2020)
  • 02 Oct 2019 Efficacy data from a phase III trial in Meningococcal-infections presented at the IDWeek 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top